TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39060934

Group type: EXPERIMENTAL
Intervention: Cognitive measurements on five cognitive domains (reasoning, working memory, processing speed, vocabulary, exploration) conducted in classrooms and at home
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Deep phenotyping sessions including structural and functional MRI, eye-tracking, parental measurements, and questionnaire-based demographic and psychosocial measures
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Baseline measures of variability
Number of subjects: 600
Study: 39060961

Group type: EXPERIMENTAL
Intervention: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long-course chemoradiation (LCRT)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long-course chemoradiation (LCRT)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Neoadjuvant long-course chemoradiation (LCRT) followed by consolidation chemotherapy
Number of subjects: 760
Study: 39060968

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB)
Number of subjects: 40
Study: 39060974

Group type: EXPERIMENTAL
Intervention: Happy, Healthy, Loved text-message program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care with attentional control text messages about infant development
Number of subjects: 62
Study: 39061093

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist, liraglutide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 39061094

Group type: EXPERIMENTAL
Intervention: 2 µM simvastatin
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Wild-type C57BL/6J mice
Number of subjects: 426

Group type: COMPARATOR
Intervention: Mice carrying a hypomorphic missense mutation in Zfp335
Number of subjects: 426
Study: 39061099

Group type: EXPERIMENTAL
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 0
Study: 39061175

Group type: EXPERIMENTAL
Intervention: High monocyte counts
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low monocyte counts
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low CD8 T-cell levels
Number of subjects: 152

Group type: COMPARATOR
Intervention: High CD8 T-cell levels
Number of subjects: 152
Study: 39061599

Group type: EXPERIMENTAL
Intervention: Maternal blood biomarker test for spontaneous preterm birth risk screening followed by preventive treatments for those screening positive.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in a clinically low-risk historical population.
Number of subjects: 0
Study: 39062003

Group type: EXPERIMENTAL
Intervention: STP1 (combination of ibudilast and bumetanide)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 39064048

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39065260

Group type: EXPERIMENTAL
Intervention: TAK-426 (10 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-426 (2 µg and 5 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39066372

Group type: EXPERIMENTAL
Intervention: Monovalent Omicron XBB.1.5-adapted BNT162b2 vaccine (30 μg)
Number of subjects: 40
Study: 39066382

Group type: EXPERIMENTAL
Intervention: Priorix vaccine (GlaxoSmithKline Biologicals)
Number of subjects: 169

Group type: COMPARATOR
Intervention: M-M-RII (Merck & Co.)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both vaccines (Priorix and M-M-RII)
Number of subjects: 169
Study: 39066557

Group type: EXPERIMENTAL
Intervention: Single-unit transcutaneous electrical nerve stimulation (Uno)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dual unit transcutaneous electrical nerve stimulation (Duo)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug use (Control)
Number of subjects: 47
Study: 39066638

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline hyclate 100 mg/day for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline hyclate 100 mg/day
Number of subjects: 0
Study: 39066746

Group type: EXPERIMENTAL
Intervention: Invisalign First Phase I treatment (CAT group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tooth-borne rapid maxillary expansion (RME group)
Number of subjects: 41
Study: 39066758

Group type: EXPERIMENTAL
Intervention: Dynamic risk modeling with a multistate model
Number of subjects: 2056
Study: 39066962

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Tumor Necrosis Factor inhibitors (TNFi)
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Non-TNF biologic DMARDs (non-TNFi)
Number of subjects: 1972
Study: 39066978

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 39067461

Group type: EXPERIMENTAL
Intervention: Nemolizumab plus TCS-TCI
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Placebo plus TCS-TCI
Number of subjects: 1728
Study: 39067465

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib-dexamethasone
Number of subjects: 302

Group type: COMPARATOR
Intervention: Carfilzomib-dexamethasone (control group)
Number of subjects: 302
Study: 39067464

Group type: EXPERIMENTAL
Intervention: CHEP-BV (cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide) followed by brentuximab vedotin consolidation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation
Number of subjects: 48
Study: 39067509

Group type: EXPERIMENTAL
Intervention: Azelastine HCl 0.15% nasal spray (2 sprays per nostril)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 110
Study: 39067513

Group type: EXPERIMENTAL
Intervention: CRP POCT
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control (no CRP POCT)
Number of subjects: 404
Study: 39067560

Group type: EXPERIMENTAL
Intervention: Transcervical balloon (Foley)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Osmotic dilators (Dilapan-S)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 39067618

Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed at discharge
Number of subjects: 2247
Study: 39067619

Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Dual-chamber pacemaker implantation with subsequent AVN ablation (PACE)
Number of subjects: 196
Study: 39067649

Group type: EXPERIMENTAL
Intervention: Ceramic partial coverage indirect adhesive restorations (PCIARs) luted with light-cured composite resin (Filtek Z250, 3 M ESPE)
Number of subjects: 60
Study: 39067764

Group type: EXPERIMENTAL
Intervention: Photovoice intervention
Number of subjects: 67
Study: 39067870

Group type: EXPERIMENTAL
Intervention: Combination of carvedilol and VBL (group C)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Group C (Combination)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Group A (Carvedilol)
Number of subjects: 330

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 330
Study: 39067873

Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg intravenously every 6 weeks plus nivolumab 240 mg intravenously every 2 weeks until disease progression or other criteria met.
Number of subjects: 21
Study: 39067876

Group type: EXPERIMENTAL
Intervention: Join4Joy approach in physical activity programmes, consisting of twelve, 1-hour weekly sessions of structured, supervised, group-based physical activity.
Number of subjects: 144
Study: 39067883

Group type: EXPERIMENTAL
Intervention: Assistance by two midwives
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Assistance by one midwife (standard care)
Number of subjects: 2221
Study: 39067885

Group type: EXPERIMENTAL
Intervention: Infection Tracking in Travellers (ITIT) app
Number of subjects: 609
Study: 39068060

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO15)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO30)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 366
Study: 39068298

Group type: EXPERIMENTAL
Intervention: Acute Coronary Syndrome (ACS)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Post-angiography group (ACS patients)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Stable Coronary Artery Disease (Control)
Number of subjects: 308
Study: 39068385

Group type: EXPERIMENTAL
Intervention: Back to Living Well program (12-week physical activity, education, and self-management program)
Number of subjects: 90
Study: 39068432

Group type: EXPERIMENTAL
Intervention: SurgeCon quality improvement program
Number of subjects: 372
Study: 39068435

Group type: EXPERIMENTAL
Intervention: 6-week progressive home-based neurodynamic exercise intervention (n=26)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Steroid injection (n=26)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Advice (n=26)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All groups (neurodynamic exercise, steroid injection, advice)
Number of subjects: 108
Study: 39068465

Group type: EXPERIMENTAL
Intervention: Intensive, family-based diet and physical activity counseling delivered by a multidisciplinary team (pediatrician, nurse, clinical nutritionist)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 80
Study: 39068739

Group type: EXPERIMENTAL
Intervention: TPIV200 + GM-CSF
Number of subjects: 120

Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 120
Study: 39068745

Group type: EXPERIMENTAL
Intervention: MG-ADL score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MG-ADL item level scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCA including MG-ADL, QMG, MG-QOL15r, EQ-5D-5L
Number of subjects: 0
Study: 39068937

Group type: EXPERIMENTAL
Intervention: Active weekly fever screening plus monthly RDT testing and treatment (group 3)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Active weekly fever screening (group 2)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Active monthly RDT testing and treatment (group 3)
Number of subjects: 906
Study: 39068945

Group type: EXPERIMENTAL
Intervention: Site-specific therapy guided by a 90-gene expression assay
Number of subjects: 182

Group type: COMPARATOR
Intervention: Empirical chemotherapy
Number of subjects: 182
Study: 39068950

Group type: EXPERIMENTAL
Intervention: Activity limitations (self-reported difficulty with walking, grasping, bending, seeing close, seeing far, speaking, hearing)
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Seeing close limitation
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Seeing far limitation
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Grasping limitation
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Bending limitation
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Speaking limitation
Number of subjects: 175660

Group type: EXPERIMENTAL
Intervention: Use of gait, visual, and hearing aids
Number of subjects: 175660
Study: 39068985

Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach with text reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailed FIT-DNA with patient support
Number of subjects: 0
Study: 39069087

Group type: EXPERIMENTAL
Intervention: Proton or photon beam therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study: 39069096

Group type: EXPERIMENTAL
Intervention: Two doses of original wild-type BNT162b2
Number of subjects: 461

Group type: COMPARATOR
Intervention: Unvaccinated (control group)
Number of subjects: 461
Study: 39069154

Group type: EXPERIMENTAL
Intervention: Psychological intervention (two, 3-hour manualized online sessions spaced 1 week apart)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 129
Study: 39069239

Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 72 Gy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 74 Gy
Number of subjects: 59
Study: 39069259

Group type: EXPERIMENTAL
Intervention: Phosphate repletion
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Daily phosphate measurements
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Follow-up for 28- and 90-day all-cause mortality
Number of subjects: 1000
Study: 39069258

Group type: EXPERIMENTAL
Intervention: Gastrointestinal Dysfunction Score (GIDS)
Number of subjects: 1400
Study: 39069269

Group type: EXPERIMENTAL
Intervention: 200 mg C15:0 daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 39069451

Group type: EXPERIMENTAL
Intervention: SMARTER intervention (family members trained to support nursing staff to take and record vital signs every 4 hours after surgery)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1395
Study: 39069466

Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI) program for 12 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal-weight individuals (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Before DI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Before and after DI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: After DI
Number of subjects: 45
Study: 39069599

Group type: EXPERIMENTAL
Intervention: EX60min (exercise 60 minutes post meal)
Number of subjects: 40

Group type: COMPARATOR
Intervention: EX120min (exercise 120 minutes post meal)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultra-rapid aspart (insulin type)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspart (insulin type)
Number of subjects: 40
Study: 39069614

Group type: EXPERIMENTAL
Intervention: Vegan diet over 8 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Omnivorous diet over 8 weeks
Number of subjects: 2
Study: 39069629

Group type: EXPERIMENTAL
Intervention: Stiffness-customized PD-AFO
Number of subjects: 20

Group type: COMPARATOR
Intervention: No AFO
Number of subjects: 20

Group type: COMPARATOR
Intervention: SOC AFO
Number of subjects: 20
Study: 39069644

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (MBSR) applied for 8 weeks, followed by individual repetition for another 8 weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 151
Study: 39069898

Group type: EXPERIMENTAL
Intervention: Y-T2D
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Y-T2D plasma-derived small extracellular vesicles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy peers
Number of subjects: 20
Study: 39069917

Group type: EXPERIMENTAL
Intervention: Untreated chronic hypertension
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Treated chronic hypertension
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: No hypertension
Number of subjects: 877

Group type: COMPARATOR
Intervention: Systolic BP reduction
Number of subjects: 877
Study: 39069967

Group type: EXPERIMENTAL
Intervention: Gefapixant 180 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 39070019

Group type: EXPERIMENTAL
Intervention: 5-min daily meditation practice
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 15-min daily meditation practice
Number of subjects: 17
Study: 39070044

Group type: EXPERIMENTAL
Intervention: Vaccinated individuals with HIV
Number of subjects: 209

Group type: COMPARATOR
Intervention: Controls (non-HIV individuals)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Former and current smoking
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Increased predicted anti-spike immunoglobulin G titer
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Booster vaccinations
Number of subjects: 209
Study: 39070173

Group type: EXPERIMENTAL
Intervention: ALARM model (deep learning radiomics with clinical variables)
Number of subjects: 1858

Group type: COMPARATOR
Intervention: High-risk group (n=221, 11.9%) and medium-risk group (n=433, 23.3%)
Number of subjects: 1858
Study: 39070176

Group type: EXPERIMENTAL
Intervention: S-UAS
Number of subjects: 320

Group type: COMPARATOR
Intervention: traditional UAS
Number of subjects: 320
Study: 39070183

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 548

Group type: COMPARATOR
Intervention: No RBC transfusion (Control)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 548
Study: 39070625

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based interventions (EBIs) including low literacy patient education, provider education, EMR tools, FIT kit distribution, and cancer control champion support.
Number of subjects: 0
Study: 39070653

Group type: EXPERIMENTAL
Intervention: MABT plus MOUD
Number of subjects: 303

Group type: COMPARATOR
Intervention: MOUD only
Number of subjects: 303
Study: 39070744

Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 201

Group type: COMPARATOR
Intervention: Written material
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Smartphone application (frequent use)
Number of subjects: 201
Study: 39070742

Group type: EXPERIMENTAL
Intervention: Focused lung, cardiac, and deep venous ultrasound
Number of subjects: 150

Group type: COMPARATOR
Intervention: Direct diagnostic imaging (control)
Number of subjects: 150
Study: 39070853

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablet
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study: 39070895

Group type: COMPARATOR
Intervention: ICOnnecta't program (control group) - a digital stepped intervention addressing psychosocial needs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cognitive module (Level 1: cognitive screening using FACT-Cog PCI; Level 2: cognitive psychoeducational campus; Level 3: online cognitive training through CogniFit software)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cognitive module integration
Number of subjects: 88
Study: 39071916

Group type: EXPERIMENTAL
Intervention: 10 mg L and 2 mg Z softgel (Carotenoid Group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard-of-care prenatal vitamins with placebo softgel (Control Group)
Number of subjects: 47
Study: 39072039

Group type: EXPERIMENTAL
Intervention: Disclosure of a polygenic risk score (PRS) for coronary heart disease (CHD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Statin therapy initiation and duration
Number of subjects: 203

Group type: COMPARATOR
Intervention: Framingham risk score (FRS)
Number of subjects: 203
Study: 39072042

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin-piperaquine+single-low dose primaquine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: Standard-of-care (SMC) with sulfadoxine-pyrimethamine+amodiaquine
Number of subjects: 6505

Group type: EXPERIMENTAL
Intervention: MDA
Number of subjects: 6505

Group type: COMPARATOR
Intervention: SMC
Number of subjects: 6505

Group type: EXPERIMENTAL
Intervention: MDA and SMC
Number of subjects: 6505
Study: 39072044

Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum block (QLB)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PENG
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: QLB
Number of subjects: 101
Study: 39072232

Group type: EXPERIMENTAL
Intervention: Fluid-sparing resuscitation strategy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 39072240

Group type: EXPERIMENTAL
Intervention: Implementation of a nephroprotective care bundle as recommended by KDIGO guidelines.
Number of subjects: 618

Group type: COMPARATOR
Intervention: Standard of care (control) group.
Number of subjects: 618
Study: 39072257

Group type: EXPERIMENTAL
Intervention: Self-disclosure
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 369
Study: 39072280

Group type: EXPERIMENTAL
Intervention: Smoking tobacco
Number of subjects: 261
Study: 39072356

Group type: EXPERIMENTAL
Intervention: Vepdegestrant (ARV-471)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant
Number of subjects: 0
Study: 39072392

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39072466

Group type: EXPERIMENTAL
Intervention: Core foot system training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional rehabilitation methods
Number of subjects: 0
Study: 39072654

Group type: EXPERIMENTAL
Intervention: Superset training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 39072750

Group type: COMPARATOR
Intervention: Tumor-infiltrating lymphocytes (TILs) in metastases
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Combined positive score (CPS)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tumor proportion score (TPS)
Number of subjects: 550

Group type: COMPARATOR
Intervention: TILs in metastases
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: PD-L1 expression
Number of subjects: 550
Study: 39073058

Group type: EXPERIMENTAL
Intervention: Partial Body Weight Support (PBWS) harness system
Number of subjects: 17

Group type: COMPARATOR
Intervention: Play without the harness engaged
Number of subjects: 17
Study: 39073142

Group type: EXPERIMENTAL
Intervention: Letrozole and Ribociclib
Number of subjects: 0
Study: 39073343

Group type: EXPERIMENTAL
Intervention: Axis-flip cases (FC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unflipped cases (UF)
Number of subjects: 84
Study: 39073370

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20